What are Prostaglandin F receptor agonist drugs?

Prostaglandin F receptor agonist drugs are pharmacologic agents that share a common mechanism (typically targeting FP prostaglandin receptor). 5 are currently marketed, with 3 more in clinical development.

What are the marketed Prostaglandin F receptor agonist drugs?

Marketed Prostaglandin F receptor agonist drugs include travoprost, latanoprost, or bimatoprost, Tafluprost 15µg/ml, Preservative-free latanoprost 50µg/ml, latanoprost 0.005% (drug), latanoprost 0.005% (Xalatan).

Prostaglandin F receptor agonist

5 marketed 1 in Phase 3 2 in Phase 2

This page covers all Prostaglandin F receptor agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting FP prostaglandin receptor, FP receptor (prostaglandin F receptor).

Targets

FP prostaglandin receptor · FP receptor (prostaglandin F receptor)

Marketed (5)

travoprost, latanoprost, or bimatoprost · Robin, Alan L., M.D. · Ophthalmology
These prostaglandin F (FP) receptor agonists increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Tafluprost 15µg/ml · Ordination Dr. Hommer · Ophthalmology
Tafluprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
Preservative-free latanoprost 50µg/ml · Medical University of Vienna · Ophthalmology
Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
latanoprost 0.005% (drug) · University Hospital, Basel, Switzerland · Ophthalmology
Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
latanoprost 0.005% (Xalatan) · Pfizer · Ophthalmology
Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.

Phase 3 pipeline (1)

APP13007, 0.05% · Formosa Pharmaceuticals, Inc. · Ophthalmology
APP13007 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension.

Phase 2 pipeline (2)

AGN-199201 ophthalmic solution · Allergan · Ophthalmology
AGN-199201 is a selective prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
AGN-195263 0.1% · Allergan · Ophthalmology
AGN-195263 is a topical ophthalmic agent that modulates intraocular pressure through enhanced aqueous humor outflow.